Aethlon Medical (AEMD) to Release Quarterly Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) is expected to issue its Q4 2026 results after the market closes on Wednesday, June 10th. Analysts expect the company to announce earnings of ($2.46) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Wednesday, June 10, 2026 at 4:30 PM ET.

Aethlon Medical Stock Performance

NASDAQ:AEMD opened at $2.13 on Friday. The firm has a market cap of $3.34 million, a P/E ratio of -0.14 and a beta of 1.49. Aethlon Medical has a fifty-two week low of $1.36 and a fifty-two week high of $29.88. The firm has a 50-day simple moving average of $2.24 and a two-hundred day simple moving average of $2.55.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors own 1.99% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Reduce”.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.